Workflow
中海医药混合A:2025年第二季度利润1994.81万元 净值增长率9.21%
Sou Hu Cai Jing·2025-07-21 10:37

Core Viewpoint - The AI Fund Zhonghai Medicine Mixed A (000878) reported a profit of 19.9481 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1045 yuan, and a net value growth rate of 9.21% during the reporting period [3][15]. Fund Performance - As of July 18, the fund's unit net value was 1.386 yuan, with a one-year cumulative net value growth rate of 31.62%, the highest among its peers [3]. - The fund's performance over different time frames includes a three-month growth rate of 23.97%, a six-month growth rate of 34.70%, and a three-year growth rate of -10.89% [4][11]. Investment Strategy - The fund focuses on innovative drugs, medical devices, and healthcare services driven by consumer upgrades, aiming to identify quality stocks with growth potential and matching valuation levels [3]. - The fund employs a bottom-up stock selection strategy, maintaining quality assets while exploring undervalued stocks to reduce portfolio volatility and provide stable long-term returns [3]. Fund Characteristics - The fund's average stock position over the past three years was 91.39%, with a peak of 93.86% by Q3 2024 [14]. - The fund has a high concentration of holdings, with the top ten stocks consistently exceeding 60% concentration over the past two years [17]. Risk Metrics - The fund's three-year Sharpe ratio is -0.0175, ranking 59 out of 105 comparable funds [9]. - The maximum drawdown over the past three years was 41.52%, with the largest single-quarter drawdown occurring in Q1 2022 at 26.04% [11].